HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Public ClinicalTrials.gov record NCT01683188. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma
Study identification
- NCT ID
- NCT01683188
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Clinigen, Inc.
- Industry
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Interventions
- vemurafenib + HD IL-2 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2012
- Primary completion
- Oct 31, 2014
- Completion
- Oct 31, 2014
- Last update posted
- Jan 31, 2021
2012 – 2014
United States locations
- U.S. sites
- 21
- U.S. states
- 17
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| Moores UCSD Cancer Center | La Jolla | California | 92093 | — |
| MSMC Research Program | Miami Beach | Florida | 33140 | — |
| Emory University School of Medicine | Atlanta | Georgia | 30322 | — |
| Loyola University Medical Center, Div of Hematology/Oncology | Maywood | Illinois | 60153 | — |
| Luther General Cancer Care Institute | Park Ridge | Illinois | 60068 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| University of Kansas | Kansas City | Kansas | 66160-0003 | — |
| Hematology/Oncology Clinic | Baton Rouge | Louisiana | 70809 | — |
| University of Michigan, Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| University of Minnesota Masonic Cancer Center | Minneapolis | Minnesota | 55455 | — |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center | New York | New York | 10032 | — |
| The Christ Hospital Cancer Center | Cincinnati | Ohio | 45219 | — |
| Case Comprehensive Cancer Center | Cleveland | Ohio | 44106 | — |
| Providence Cancer Center | Portland | Oregon | 97213 | — |
| St. Luke's Hospital, Anderson Campus | Easton | Pennsylvania | 18045 | — |
| UPMC Cancer Centers | Pittsburgh | Pennsylvania | 15232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01683188, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 31, 2021 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01683188 live on ClinicalTrials.gov.